Phaseline

Companies › Gliknik

Gliknik: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GL-2045
IVig-like mechanism for platelet responses in ITP
–Phase 1Immune ThrombocytopeniaDec 2027
GL-0719–Phase 1First in Man Study to Evaluate Initial Safety–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05318534GL-0719Phase 1First in Man Study to Evaluate Initial SafetyOtherJun 2026
NCT07605845GL-2045Phase 1Immune ThrombocytopeniaHematologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.